The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Acalabrutinib-obinutuzumab in CLL: 3-year follow-up
The combination of acalabrutinib with obinutuzumab was investigated for the treatment of chronic lymphocytic leukemia (CLL) in the Phase 1b/2 ACE-CL-003 study (NCT02296918). Here, Kerry Rogers, MD, from the Ohio State University, Columbus, OH, discusses the 3-year follow-up. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
